U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H18N6O8S3
Molecular Weight 542.566
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFONICID

SMILES

[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C4=CC=CC=C4)C(O)=O

InChI

InChIKey=DYAIAHUQIPBDIP-AXAPSJFSSA-N
InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H18N6O8S3
Molecular Weight 542.566
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Cefonicid is a semi-synthetic broad-spectrum cephalosporin antibiotic resistant to beta-lactamases. Similarly to other cephalosporins, cefonicid exerts its antibacterial activity through the inhibition of the bacterial cell-wall synthesis. Its in vitro and in vivo activity against a wide range of Gram-positive and Gram-negative microorganisms is documented.

Originator

Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/cefonicid.html

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MONOCID

Approved Use

Treatment of serious bacterial infections caused by microorganisms susceptible to cefonicid. Studies on specimens obtained prior to therapy should be used to determine the susceptibility of the causative organisms to cefonicid. Therapy with cefonicid may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. CEFONICID TEVA is indicated in the treatment of the infections of the lower respiratory tract, urinary tract, skin and skin structure, bone and joints. In the treatment of the above-mentioned infections, the product is particularly used in weak and/or immuno-depressed patients. Surgical Prophylaxis: The administration of a single 1 g dose of CEFONICID TEVA before surgery may reduce the incidence of post-operative infections, caused by susceptible microorganisms, in patients undergoing surgical procedures classified as contaminated or potentially contaminated, or in patients in whom infection at the operative site would present a serious risk; providing protection during all the surgery period and for about 24 hours following administration. Supplementary doses of CEFONICID TEVA may be administered for two additional days to patients undergoing prosthetic arthroplasty. In cesarean section, the intra-operative administration of CEFONICID TEVA (after the umbilical cord has been clamped) reduces the incidence of post-operative sepsis.

Launch Date

4.54031999E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
127 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFONICID serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
213 μg/mL
50 mg/kg bw single, intramuscular
dose: 50 mg/kg bw
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFONICID serum
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1644 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFONICID serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.11 μg × h/mL
50 mg/kg bw single, intramuscular
dose: 50 mg/kg bw
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFONICID serum
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.6 h
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFONICID serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.24 h
50 mg/kg bw single, intramuscular
dose: 50 mg/kg bw
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFONICID serum
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 g single, intramuscular
Dose: 1 g
Route: intramuscular
Route: single
Dose: 1 g
Sources:
unhealthy, 19 - 88 years
n = 57
Health Status: unhealthy
Age Group: 19 - 88 years
Sex: M+F
Population Size: 57
Sources:
1 g single, intravenous
Dose: 1 g
Route: intravenous
Route: single
Dose: 1 g
Sources:
unhealthy, 19 - 88 years
n = 57
Health Status: unhealthy
Age Group: 19 - 88 years
Sex: M+F
Population Size: 57
Sources:
50 mg/kg single, intramuscular
Dose: 50 mg/kg
Route: intramuscular
Route: single
Dose: 50 mg/kg
Sources:
unhealthy, 36 -142 months
n = 17
Health Status: unhealthy
Condition: respiratory infection | urinary tract infection
Age Group: 36 -142 months
Sex: M+F
Population Size: 17
Sources:
2 g 2 times / day single, intravenous
Highest studied dose
Dose: 2 g, 2 times / day
Route: intravenous
Route: single
Dose: 2 g, 2 times / day
Sources:
unhealthy, 59.9 ± 10.74 years
n = 30
Health Status: unhealthy
Condition: Spontaneous bacterial peritonitis
Age Group: 59.9 ± 10.74 years
Sex: M+F
Population Size: 30
Sources:
PubMed

PubMed

TitleDatePubMed
Ertapenem: a new carbapenem.
2001 Jun
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Empiric treatment with once-daily cefonicid and gentamicin for febrile non-neutropenic pediatric cancer patients with indwelling central venous catheters.
2008 Jul
Patents

Patents

Sample Use Guides

The usual adult dosage is 1 g CEFONICID administered once every 24 hours, intravenously or by deep intramuscular injection. Daily doses higher than 1 g are rarely necessary. However, in exceptional cases, doses up to 2 g given once daily have been well tolerated. In case of administration of 2 g I.M. once daily, half the dose should be administered in different large muscle masses.
Route of Administration: Other
In Vitro Use Guide
The MIC50 and MIC90 for the 60 strains of viridans group streptococci isolated from blood of patients with bacteremia and infective endocarditis were 4 and 32 micrograms/ml for cefonicid.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:16:10 UTC 2023
Edited
by admin
on Sat Dec 16 16:16:10 UTC 2023
Record UNII
6532B86WFG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFONICID
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
CEFONICID [VANDF]
Common Name English
Cefonicid [WHO-DD]
Common Name English
MONOCEF
Brand Name English
cefonicid [INN]
Common Name English
CEFONICIDE
Common Name English
CEFONICID [MI]
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2R)-2-HYDROXY-2-PHENYLACETYL)AMINO)-8-OXO-3-(((1-(SULFOMETHYL)-1H-TETRAZOL-5-YL)THIO)METHYL)-, (6R,7R)-
Common Name English
(6R,7R)-7-(((2R)-2-HYDROXY-2-PHENYLACETYL)AMINO)-8-OXO-3-(((1-(SULFOMETHYL)-1H-TETRAZOL-5-YL)THIO)METHYL)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
Classification Tree Code System Code
WHO-ATC J01DC06
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
WHO-VATC QJ01DC06
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
NCI_THESAURUS C357
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
LIVERTOX NBK548666
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
Code System Code Type Description
CHEBI
3491
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
PUBCHEM
43594
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
EPA CompTox
DTXSID7022758
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
CAS
61270-58-4
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
MERCK INDEX
m3200
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
CEFONICID
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
ChEMBL
CHEMBL1601
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
DRUG BANK
DB01328
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
SMS_ID
100000078729
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
DRUG CENTRAL
542
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
FDA UNII
6532B86WFG
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
RXCUI
2183
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY RxNorm
EVMPD
SUB12429MIG
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
NCI_THESAURUS
C65299
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
MESH
D015790
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
INN
4479
Created by admin on Sat Dec 16 16:16:11 UTC 2023 , Edited by admin on Sat Dec 16 16:16:11 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
INTERMEDIATE -> INGREDIENT
Related Record Type Details
ACTIVE MOIETY